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Abstract 
 
Background: Coronary Microvascular Dysfunction (CMVD), affects the smaller vasculature 
and is difficult to diagnose without invasive tests. Little is known about the relationship between 
movement behaviours and CMVD, which may offer insight for primary prevention and early 
management. Objective: Examine and compare patterns of obesity, metabolic health, and 
movement behaviors amongst patients with CMVD and epicardial disease. Methods: The 
relationship between metabolic health, movement behaviors, and CMVD were estimated by 
logistic regression (unadjusted and adjusted for confounders). Results: Sleep quality and 
quantity were significantly worse in those with suspected coronary microvascular dysfunction. 
Physical activity was not significantly different between referral groups. Interestingly, obese-
CMVD patients were 31.7% more likely to have suspected CMVD compared to their normal 
weight counterparts.  Conclusions: Despite a relatively high prevalence of inactivity, sleep 
disturbance, MetS, and general and abdominal obesity, patterns of lifestyle factors did not 
materially differ between cases of suspected CMVD and epicardial disease. 
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1.0  Introduction 
 
Cardiovascular disease (CVD) is one of the largest causes of death worldwide, 
responsible for approximately 30% of deaths globally (1). Within Canada, approximately one-
third of all deaths are attributable to CVD, making it the second leading cause of death within the 
nation (1). It is no surprise that heart disease imposes major financial costs within the nation, 
with CVD costing the Canadian government $21 billion per year in direct and indirect costs (1). 
Coronary artery disease (CAD), one of the many sub-groups of CVD, accounts for 29% of all 
deaths (2), and can be further refined into two larger categories based on the type of coronary 
vasculature at risk. Well-known macrovascular issues often include the presence of blockages in 
large vessels surrounding the heart, secondary to atherosclerosis, known as obstructive CAD (3), 
or which may be referred to as traditional epicardial CAD in this study.  A commonly accepted 
cut-off for obstructive CAD consists of stenosis, or narrowing of the artery, of 70% in a main 
coronary artery (3). Such macrovascular concerns may also include mechanical problems, such 
as coronary artery spasms and myocardial bridging. Comparatively, microvascular-related issues 
been shown to increase coronary resistance in the smaller vessels around the heart, with the 
potential of progressing into future cardiac complications (3). 
 Currently, several competing theories surrounding the pathophysiology of coronary 
microvascular dysfunction (CMVD) exist. Some studies have hypothesized that the cause of 
CMVD can be attributed to a reduced nitric oxide release, ultimately impairing endothelium-
dependent vasodilation (4). Moreover, a limited number of studies have suggested that CMVD is 
heavily influenced by endothelial progenitor cell abnormalities (4).  The most common theory 
regarding the pathophysiology of microvascular dysfunction is an increase in resistance and 
obstructed blood circulation within the arterioles surrounding the heart (5). Microvascular 
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dysfunction is especially concerning as it is often undetected in patients, particularly women, 
with symptoms of angina who otherwise present as “normal” upon coronary angiography (6) and 
are often quickly discharged and told that they are not at imminent risk of a cardiac event. 
However, upon further follow-up, up to 65% of these same patients have evidence of 
microvascular dysfunction, a condition referred to as Functional Coronary Artery Disease 
(Functional CAD) (6). 
Despite the many non-modifiable risk factors, approximately 80% of CAD-related events 
are a result of lifestyle-related factors (7).  These modifiable behaviours have also been shown to 
play a large role in the development of functional CAD (8), with factors ranging from poor 
quality and duration of sleep, increased mental stress, and a sedentary lifestyle. It remains 
unclear whether these lifestyle factors are a pre-cursor to microvascular dysfunction or whether 
the presence of these risk factors brings rise to new comorbidities, such as metabolic syndrome 
(MetS), as they are all heavily interconnected. It is for this reason that it is necessary to work 
towards identifying the contributing factors in order to help screen and prevent disease 
progression in patients at greatest risk of CMVD.  
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2.0  Literature Review 
2.1   Metabolic Syndrome and Coronary Microvascular Dysfunction  
 
As defined above, MetS consists of a combination of metabolic abnormalities that play a 
significant role in the progression of both cardiovascular diseases and type 2 diabetes mellitus 
(9). According to the National Cholesterol Education Program - Third Adult Treatment Panel 
(modified NCEP ATP III) (10), the diagnostic criteria for MetS requires the presence of 3 out of 
5 of the following characteristics: increased waist circumference (>102 cm [>40 in] for men, >88 
cm [>35 in] for women), elevated triglycerides (≥150mg/dl), low HDL cholesterol (<40 mg/dl in 
men, <50 mg/dl in women), hypertension (≥130/ ≥ 85 mmHg), and impaired fasting glucose 
(≥100 mg/ dl) (11). The severity of the condition has not gone unnoticed, as individuals with 
MetS have a two-fold elevated risk of all-cause mortality, and a three-fold elevated risk of 
diabetes, as compared to those without MetS (12) ultimately marking MetS as an early warning 
sign for impending health risk.  
Cross-sectional studies have shown that almost one third of the Canadian population has 
MetS. Although the pathways linking the various components of MetS are not fully understood, 
an increase in intima-media thickness, arterial stiffness, systemic inflammation, and other factors 
have been implicated in the onset of hypertension, serving as a domino effect for many of these 
related chronic conditions (13, 14, 11). As the components of MetS are also considered classic 
CAD risk factors, the risk of developing cardiovascular and coronary diseases increases 
significantly with MetS (14). For example, in a study of 811 patients with and without MetS, 
Espinola-Klein et al. (15), MetS was found to be an independent risk factor for cardiovascular 
events (15). Similarly, in a study by Kazlauskienė et al (2015), more than half of all patients with 
acute coronary syndrome were also diagnosed with MetS (16). One previous study has examined 
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the co-occurrence of MetS and CMVD in a clinical setting (17), results of which suggest that 
microcirculatory dysfunction may be strongly associated with MetS. While insulin resistance and 
hypertension may be particularly affected, additional work is necessary to assist in identifying 
CMVD patients who might be missed through traditional measures of coronary dysfunction. 
2.2       Microvascular Disease in Women  
Although heart disease has always been thought of as a “man’s disease,” recent research 
has shown that women are more susceptible to developing microvascular disorders when 
compared to men (18). Specifically, approximately 60% to 70% of women who undergo 
coronary angiography are found to have functional CAD as opposed to only 30% of men. To 
expand on this, women are more likely to have “normal” coronary arteries upon coronary 
angiograph (19) when compared to men, as more than 50% of women who undergo cardiac 
catheterization as a result of chest pain display non-obstructive coronary arteries, or “smooth 
lesions” (20).  In a study by Humphries et al. (2008), re-hospitalization within 180 days for acute 
coronary syndrome or chest pain in patients with "normal" angiography was four-fold higher for 
women as compared to men (21). This high rate of recurrence is echoed in results of the 
Women’s Ischemia Syndrome Evaluation (WISE) study wherein more than 40% of women with 
non-obstructive coronary disease and evidence of myocardial ischemia were re-hospitalized for 
chest pain on multiple occasions, and 30% of these women were re-admitted for an additional 
coronary angiogram within 5 years of their initial visit (20).  
Despite the seemingly normal looking arteries, one study observed a 20% mortality rate 
in patients with poor coronary flow reserve as opposed to only 7% of those with normal coronary 
flow reserve (22). Additionally, microvascular dysfunction has been shown to lead to traditional 
obstructive CAD (23). In one study, 30% of patients with suspected microvascular dysfunction 
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developed obstructive CAD within 10 years of initial assessment (23). As coronary heart disease 
is the leading cause of death amongst women (24) in the U.S. - with approximately two-thirds of 
women having no previous symptoms (25) - these findings suggest that appropriate screening 
tools for CMVD is imperative. Women are not only more likely to develop CMVD but are also 
more at risk at being clinically overlooked. Studies have shown that women are less likely to 
receive extensive cardiac investigation of symptoms (26) and are less likely to receive treatment 
for thrombolysis (27) angioplasty or cardiac surgery (28) upon consultation. It is for this reason 
that females are considered to be an “under-represented” population when compared to men, as 
their symptoms are most often depicted as benign and low-risk.  
 
2.3       Relationship between BMI and Microvascular Dysfunction 
  It is well-understood that in most traditional CAD cases, as body mass index increases, so 
does one’s risk of developing cardiac abnormalities. This is often the result of atherosclerosis 
(29) or the build-up of plaque on vessel walls, which ultimately impedes coronary flow.  
However, a recent study by Van Der Heijden et al. (2017) also looked at the influence of obesity 
in patients with microvascular endothelial dysfunction and compared the results to traditional 
risk factors, such as diabetes, smoking, hypertension, etc., in patients with suspected CAD (30). 
It was found that in the 108 patients examined, that an increased body mass was associated with 
reduced endothelial function upon adjustments for existing comorbidities (30). It has been 
hypothesized that higher body mass is detrimental to endothelial function as a result of increased 
adipose-related secretions, and an imbalance in healthy perivascular adipose tissue (PVAT) from 
non-obese patients (31); all of which are essential to maintaining healthy endothelial function.  
Another recent and larger study by Bajaj et al. (2018) examined 827 patients without traditional 
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obstructive CAD with those with symptoms of coronary microvascular dysfunction, defined as 
having impaired coronary flow reserve (CFR). Results of this study demonstrated an inverted J-
shape relationship between BMI and CFR wherein at low levels of BMI, CFR decreased, and 
amongst those at higher BMI, CFR was increased (32).  
 
2.4       Sleep Duration and Quality on Microvascular Dysfunction 
Although it is well-established that one’s overall quality of life is often compromised 
following a significant cardiac event (33), the reverse may also be true (34). Common sleep 
disorders affecting both sleep quality and duration, such as sleep apnea and obstructive sleep 
disorder, have been shown to be independently associated with atherosclerosis and heart 
remodeling (35). However, it is difficult to discern the relative importance of sleep quality and 
quantity in the development of cardiovascular diseases, as sleep duration may increase as a result 
of poor-quality sleep, particularly in patients with pre-existing medical conditions (36).  
A number of studies to date have investigated the relationship between sleep dysfunction 
and cardiovascular health. For example, in a study of the effects of sleep duration and quality 
over a span of 10-15 years, it was observed that short sleepers with poor sleep quality had a 63% 
higher risk of CVD and a 79% higher risk of CHD incidence in comparison to normal sleepers 
with good sleep quality (37). In addition to this, a prospective study aimed at investigating the 
relationship between obstructive sleep apnea (OSA) and CAD also demonstrated that the 
treatment of OSA was associated with a decrease in the number of cardiac events occurring in 
patients with both chronic conditions, as well as a decrease in the time to a cardiac event (38). 
Many patients with OSA have also been found to have hypertension, which has been associated 
to a number of microvascular conditions, such as perivascular fibrosis, a reduction in the number 
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of capillaries per gram of muscle tissue, reduced vascular lumen, as well as coronary 
microvascular anomalies (38). Finally, the Wisconsin Sleep Cohort Study, a recent longitudinal 
analysis, found similar results upon examining over a thousand individuals with sleep-disordered 
breathing (SDB). Over the span of 24 years it was observed that participants with severely 
untreated SDB were 2.6 times more likely to develop CHD or heart failure, even after adjustment 
for confounders (39).  
Beyond the studies described above, the relationship between more general patterns of 
sleep and microvascular dysfunction is an area of emerging research interest, given that impaired 
microvascular function is often a pre-cursor in the development of cardiovascular disease (40). 
Indeed, poor sleep patterns are believed to impact microvasculature as a result of systemic low-
grade inflammation (41). In a study of healthy adults in Amsterdam (42), despite the finding of 
no significant relationship between sleep quality on microvascular function in women, men with 
poor sleep patterns were shown to have decreased capillary recruitment, and ultimately, reduced 
microvascular function. Findings such as these have led some researchers (43) to theorize that 
certain sleep disorders, such as SDB, may be the driving force behind the development of 
endothelial dysfunction, systemic inflammation, and insulin resistance as a result of chronic 
nocturnal hypoxemia during sleep (43). Despite the uncertainty surrounding the etiology of 
microvascular dysfunction, it remains clear that both sleep duration and quality are important 
risk factors to consider and further examine in the development of CMVD.  
2.5      Physical Activity, Sitting Time and Microvascular Dysfunction  
Not unlike most chronic conditions, physical inactivity has been shown to have 
significant effects on the development of both traditional macrovascular heart disease and 
functional CAD (44).  While research on lifestyle related risk factors and CMVD is still in its 
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infancy, considerable evidence now supports current physical activity guidelines, stating that 
engaging in 150 minutes of moderate-to-vigorous physical activity per week or more is 
associated with a graded reduction in mortality and major cardiovascular diseases (45, 46). 
While there are a number of mechanisms at play, activating large muscle groups by means of 
physical activity can increase peak aerobic capacity, which is itself inversely related to all-cause 
mortality in patients with CAD (47). Although the benefits of physical activity are well 
established and highly promoted, research now suggests that maintaining an active lifestyle is 
just as beneficial as in engaging in intentional physical activity (48). More specifically, Kulinski 
et al. (2014) demonstrated that sitting for 6-7 hours can actually negate the effects of one-hour of 
moderate level exercise per day. Although it remains unclear which of the two is ideal for 
improving heart (and specifically microvascular) health, it remains evident that both engaging in 
regular exercise or maintaining an active lifestyle is necessary to reduce one’s risk of developing 
future cardiac events. The systemic consequences of regular activity include an increase in the 
body’s demand for myocardial oxygen, thus increasing coronary blood flow, and with continued 
training, cardiovascular adaptation can reduce the risk of myocardial infarctions and symptoms 
of angina (49). This is especially important in aiding in the prevention of microvascular 
dysfunction, as many patients with microvascular disorders display patterns of significant arterial 
stenosis, a consequence of limited coronary blood flow (49). As discovered by Hanna et al. 
(2014), exercise training was found to reduce resistance vessel hypertrophic remodeling and 
vessel stiffness, while helping to re-establish myogenic responsiveness and improving epicardial 
microcirculation (50). This suggests that chronic physical activity is not only important for the 
prevention of microvascular diseases, but also contributes to the reduction in cardiac outcomes 
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post-diagnosis. 
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3.0  Study Rationale 
  A number of modifiable and non-modifiable factors impact the risk of traditional 
epicardial CAD. Previous research has shown that modifiable lifestyle factors, such as smoking, 
diabetes mellitus, hypertension, and hyperlipidemia (51), play a large role in the development of 
CMVD. However, much less is known about the interaction of these factors on the development 
and progression of microvascular dysfunction. As most individuals with microvascular 
dysfunction have “normal” looking arteries and do not have signs of arterial blockages, 
microvascular dysfunction is often seen as a relatively benign (52) condition that is often masked 
by traditional epicardial symptoms (51). However, it has recently come to light that those 
without visible CAD have an increased risk of adverse cardiac events (53), further emphasizing 
the importance of understanding the role of microvascular dysfunction in the development and 
progression of the disease. 
 The purpose of this study is to therefore to i) explore the relationship between early onset 
metabolic dysfunction (MetS and obesity) that may precede or co-occur and may be early 
warning signs for microvascular dysfunction, and; ii) examine the relationship between 
modifiable lifestyle-related risk factors (sleep, physical activity, and sitting time) and 
microvascular disease. Ultimately, this information aims to explore how individuals with 
microvascular dysfunction may differ in lifestyle factors from those who are diagnosed with 
more traditionally epicardial CAD. The following analyses will serve as a preliminary step to 
understanding the association between potential risk factors in microvascular dysfunction and its 
subsequent progression to debilitating cardiovascular conditions. 
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4.0 Objectives 
The thesis aims to characterize the movement (PA) and non-movement (sedentary time, 
sleep) behaviors of patients with functional CAD, and see if it differs from the traditional CAD 
population. 
Specific Aim 1: To examine the metabolic risk factors involved in patients with suspected 
CMVD in comparison to those with Epicardial disease. 
Specific Aim 2: To describe patterns and examine existing associations between movement 
behaviour physical activity, sitting time, and sleeping patterns in patients with microvascular 
dysfunction. 
Specific Aim 3: To estimate the odds of developing CMVD according to movement behaviour. 
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5.0 Methods 
 
5.1 Participants and Data Collection        
Data for this study is abstracted from the Advanced Coronary Physiology Program (ACPP) 
data registry at Southlake Regional Health Centre (SRHC) in Newmarket, Ontario. All patients 
referred to the physiology clinic at SRHC from January 2019 – March 2019 with possible CAD 
were eligible for the study. All patients provided verbal informed consent, and ethical approval 
was obtained from the Research Ethic Board at Southlake Regional Health Centre. Patient 
information was accessed through an anonymized dataset provided by the study PI and lead 
cardiologist, with geographic identifiers stripped to reduce the potential for residual disclosure. 
Inclusion Criteria 
        Referrals for these patients were accepted from specialists throughout the region. A total of 
594 patients were seen in the cardiology clinic, however 158 follow-up patients were excluded 
from the analysis (Figure 1) as this study focuses on initial consultations.  A total of 436 patients 
were therefore included in the final analysis. SRHC referrals for patients with obstructive CAD 
were included to allow for a direct comparison of the similarities and differences of patients with 
suspected functional CAD for this thesis.  
5.2 Study Variables 
Dependent Variables 
  There are three outcome variables of interest in this study; CMVD, Epicardial and 
Unconfirmed referral groups. Both CMVD and Epicardial patients are classified based on 
baseline physician diagnosis.  
Dependent Variables 
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Patient referral category were sorted into three diagnostic groups, functional CAD, 
epicardial CAD or ‘Unconfirmed, based on a combination of medical history and clinical tests 
examined by the lead cardiologist at SRHC.  
Independent Variables 
  Independent variables include i) self-reported questionnaires (socio- demographics, sleep 
quality and quantity, weight history, physical activity, sedentary time, attitudes towards exercise, 
and health-related quality of life); ii) anthropometric measures (body mass index (BMI: kg/m2) 
and waist circumference (WC), and; iii) measures of blood chemistry (e.g. triglycerides, high-
density lipoprotein cholesterol, and fasting blood glucose) necessary to identify the presence of 
MetS (Appendix A). 
Metabolic Syndrome (MetS) 
  Metabolic syndrome is defined as having 3 out of 5 of the following characteristics: 
increased waist circumference (>102 cm [>40 in] for men, >88 cm [>35 in] for women), elevated 
triglycerides (≥150mg/dl), low HDL cholesterol (<40 mg/dl in men, <50 mg/dl in women), 
hypertension (≥130/ ≥ 85 mmHg), and impaired fasting glucose (≥100 mg/ dl) (NCEP ATP III) 
(29).  
Sleep Quality 
  Sleep quality was assessed using the STOP-BANG questionnaire, a widely used 
screening tool for Obstructive Sleep Apnea. The STOP-BANG questionnaire (Appendix B) 
consists of 4 STOP questions related to perception of sleep quality and sleep-related behaviour, 
and 4 additional questions regarding patient sociodemographic characteristics that are known to 
increase risk of sleep apnea. Patients were subsequently classified as “low risk” if they answered 
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‘yes’ to less than 3 questions, “intermediate” if they answered ‘yes’ to 3-4 questions, and “high” 
OSA risk groups if they answered ‘yes’ to 5-8 questions on the STOP-BANG questionnaire. 
Sleep Duration 
 Sleep duration criteria were informed by a recent study by Kwok et al. (2018) wherein 
there was a U-shaped relationship between sleep duration on cardiovascular events (54). 
Consequent to this, patients in the “low risk” category included those who self-reported sleeping 
6-8 hours per night, whereas those in the “high risk” groups had less than 6 hours of sleep or 
more than 9 hours of sleep. 
Physical Activity 
  As recommended by the Canadian Physical Activity Guidelines (Canadian Society for 
Exercise Physiology, 2012), individuals are deemed physically active if they accumulate more 
than 150 minutes of moderate to vigorous physical activity per week (55). Patients were asked 
during their visit with their cardiologist if they “perform at least 150 minutes of moderate 
physical activity per week.” As a result, patients were deemed either physically inactive or active 
based upon the physical activity cut-offs.  
 
Sedentary Time 
  Participants were asked “in a typical day, of your working hours, how much time do you 
spend sitting.” Those who spent less than, and including, half their waking hours sitting were 
deemed non-sedentary. Those who answered that they spent more than half their waking hours 
sitting were categorized as “sedentary” (56). 
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Cardiac Syndrome X, Y 
  When possible, participants were classified as either suspected syndrome X or syndrome 
Y cases based on clinician diagnosis. These variables will be briefly examined due to emerging 
data that characterizes microvascular dysfunction amongst those with both cardiac syndrome X 
and cardiac syndrome Y (57, 42). 
5.3      Statistical Analysis 
  Data are expressed as mean ± S.D for continuous variables and number and percentage 
for categorical variables. As not all participants answered the same questionnaires, pairwise 
deletion methods were employed in order to obtain maximize sample size. Comparisons between 
referral categories and continuous variables were completed using a one-way analysis of 
variance. Comparisons between categorical groups were performed using χ²-tests for 
independence. Logistic regression was performed in three different models to investigate the 
relationship between BMI, sleep quality, physical activity, and sedentary behaviour on referral 
category. Model 1 is unadjusted, model 2 is adjusted for age- and sex-adjusted, and model 3 is 
adjusted for BMI, sex, age, sleep, exercise and sedentary behaviour. Odds ratios with 95% 
confidence intervals are presented. For all analyses, statistical significance was judged at an 
alpha level of 0.05. All statistical analyses were performed using SAS version 9.4 (Cary, NC).  
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6.0  Results 
 Baseline descriptive characteristics for participants are found in Table 1, classified by 
referral diagnosis. Overall, study participants are predominantly white (82.4%), married (71%) 
men (54.7%), with full-time employment (43.2%) at the time of first clinic visit. Almost half of 
participants (49.3%) had a history of smoking cigarettes and 41% reported daily alcohol 
consumption, whereas only 12.4% had ever used cannabis products. Notably, the frequency of 
males and females seems to be inversed in the Epicardial group when compared to the CMVD 
group; 60.1% of the CMVD population consists of females, whereas only 31.2% of Epicardial 
participants are female. 
 Table 2 shows the metabolic characteristics by referral category of study participants.  
CMVD patients tended to have a higher mean age (CMVD: 62.0 y vs Epicardial: 58.5 y). 
Overall, there were no observable differences found in anthropometric measures; mean BMI 
within all three referral groups were all close to 27 kg/m², implying that most patients were 
classified as overweight. Mean waist circumference and the prevalence of abdominal obesity was 
also similar between all three groups. Metabolic factors, such as mean fasting glucose and mean 
systolic and diastolic blood pressure, were also similar across referral groups, whereas the 
CMVD group had lower mean triglycerides (1.2 ± 0.6 mmol/L), HDL (1.4 ± 0.4 mmol/L) and 
LDL (1.5 ± 0.7 mmol/L) when compared to both Epicardial (1.6 ± 1.1 mmol/L,  1.5 ± 0.8 
mmol/L, and 2.2 ± 0.9 mmol/L) and unconfirmed (1.5 ± 1.0 mmol/L,  1.4 ± 0.7 mmol/L, and 1.9 
± 0.9 mmol/L) categories.  The majority of patients fell within the normal ranges for blood 
pressure at the time of examination, as only 11% of all patients had elevated blood pressure. 
Nonetheless, almost a quarter (24.8%) of all participants met the MetS criteria (>3 out of 5 risk 
factors), with a higher frequency found in those with CMVD (28%) when compared to 
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Epicardial (22%) and Unconfirmed (20%). In addition, 29% of CMVD participants had ‘High’ 
CRP levels compared to 18.1% of Epicardial patients, and 17.2% out of those that are 
Unconfirmed. This is to say that participants were divided almost equally amongst CRP level 
groups in those with CMVD, whereas the bulk of participants in both Epicardial and 
Unconfirmed groups were in low (50%) and intermediate (58.6%) CRP level groups, 
respectively.  
Table 3 shows patient-reported health outcomes by referral category. According to 
patient reports, myocardial infarctions (MI) are the most prevalent amongst all three referral 
groups, with hypertension closely following (49%). Almost three quarters (74.1%) of the 
epicardial participants had reported a previous MI, in comparison to only 39.4% in those with 
CMVD. remains to be a recurring concern in almost half of the study population (49%). 
Significance was found in patients reporting a history of osteoarthritis (CMVD: 4.3% vs 
Epicardial: 3.5%), gastroesophageal (CMVD: 17.8% vs Epicardial: 9.4%) and anxiety (CMVD: 
16.3 % vs Epicardial: 5.8%) concerns. In each case, CMVD patients had a higher frequency 
when compared to Epicardial and Unconfirmed groups.  
Figure 2 illustrates CMVD subtypes, divided by syndrome X, syndrome Y, and other, by 
gender. Most participants are grouped within ‘syndrome X’ category (39.9%), with only 30.8% 
of participants are suspected syndrome Y participants, and 29.3% were grouped as ‘Other.’ 
Amongst CMVD patients, approximately 61.4% of Syndrome X patients are females, and 38.8% 
males. Comparatively, 64.0% of Syndrome Y participants are females, with males encompassing 
the remaining 36.0%.  
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In terms of movement behaviors, no difference in meeting PA guidelines across referral 
categories was observed (Table 4). CMVD: 51.8% of CMVD patients are meeting recommended 
guidelines, while 48.2% that are not. In contrast, 63.4% of Epicardial patients are meeting 
guidelines; the remaining 44.7% have stated that they do not complete 150 minutes of moderate 
exercise per week (Table 4). Sitting time and online screen time (Table 4) follow similar patterns 
in that very few clinic patients report sitting almost all of the day (4.4%), and approximately one-
quarter (25.1%) of participants reported being on the computer for less than 2 hours per day. 
When examining risk of sleep apnea with the STOP-BANG criteria (Table 4), the majority of 
participants in all three referral groups were classified as either low or intermediate risk. Over 
one-quarter of epicardial patients were classified in the high-risk STOP-BANG group, closely 
followed by the CMVD group (24.9%) and the Unconfirmed group (24.1%). Interestingly, 
CMVD patients showed signs of poor sleep patterns, as there was almost double the number of 
CMVD patients that slept for less than 5 hours a night (20.2% vs Epicardial: 11.6%). These 
trends are seen again when assessing self-perceived sleep quality amongst referral groups, as less 
than half of the CMVD patients (40.9%) revealed that they woke up feeling more rested, in 
comparison to 57.3% of Epicardial patients that wake up feeling rested. A significant proportion 
of CMVS participants (77.7%) have reported feeling fatigued during the day, in contrast to only 
59.8% of Epicardial patients and 53.1% of unconfirmed cases that report feeling fatigued.  
Table 5 examines sitting time, physical activity, and sleep quality and quantity amongst 
CMVD-BMI groups. Amongst participants with CMVD and classified as under/normal weight, 
77.6% report sitting for less than half the day, and 65.3% state that they are meeting minimum 
PA guidelines.  Similarly, 73.9% of those in overweight groups along with 63.3% in obese 
groups have indicated that they sit for less than half the day, and approximately half of both 
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groups are meeting minimum exercise guidelines (50% and 43.3% respectively). Strikingly, 
49.2% of participants of obese-CMVD groups are at high risk of sleep apnea, compared with 
only 3.8% of those in the under/normal weight groups. 
Results of the logistic regression analysis in Table 6 demonstrate that when adjusted for 
all variables, those in the obese BMI category had 1.32 greater odds of suspected CMVD when 
compared to those in the underweight/normal groups. When adjusting for all confounding 
variables, those who reported feeling fatigued during the day had more than a twofold increase 
(OR: 2.27 [95% CI: 1.06- 4.88]) in odds of suspected CMVD than those who answered ‘no’ to 
the same question. Similarly, those who answered ‘no’ to feeling rested in the unadjusted group 
had a 37% increase in odds (OR: 1.37 [95% CI: 0.74 – 2.55]) of being classified as CMVD than 
those who answered ‘yes.’ Those in the higher risk, but not intermediate risk CRP level 
categories had a little over twice the odds  (OR: 2.09 [95% CI: 1.05 – 4.14]) of being a suspected 
CMVD case than those in the lower risk CRP level group. Finally, despite trends for difference 
in CMVD at the descriptive level, no significance was discovered between sexes, regardless of 
adjustments.  
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7.0  Discussion 
 This study aimed to compare patterns of sociodemographic, medical, and health behavior 
factors between coronary epicardial and CMVD patients in a clinical setting. Specifically, this 
study explored potential differences in existing risk factors between diagnostic groups, many of 
which were modifiable in nature.  Notably, sleep quality was found to differentiate CMVD, with 
non-significant findings for other movement and non-movement behaviors. Although distinct 
differences in the prevalence of obesity, inflammation, and MetS were not found, the overall 
patterns suggest the need for additional work.  
CMVD Participant Profiles 
 Despite functional differences in the vasculature between CMVD and traditional CAD 
groups, CMVD participants patient profiles closely resembled those of epicardial patients. 
Patients in all three referral groups were predominantly white and married, although this may be 
a result of the overall demographic of the city hospital. Patients also had similar mean ages, 
around 60 years of age. In terms of anthropometrics, average BMI and WC were similar across 
groups (mean: 27.8 kg/m2), signifying that a majority of the CAD population were classified as 
overweight. Previous larger studies, such as the Framingham Heart Study and the Nurses’ Health 
Study (58, 59) have all identified increased rates of CAD-related mortality in individuals 
classified with overweight or obesity. Larger studies of the same caliber are less frequent with 
respects to CMVD, however a large meta-analysis of over 44,000 individuals found that an 
increased BMI was also associated with elevated risks of narrowed arteriolar and wider retinal 
venular caliber (29) ultimately leading to microvascular impairments. It is therefore not 
surprising that no changes were observed between both groups, considering that an elevated BMI 
have been proven risk factors for both obstructive CAD and CMVD alike. 
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Variation in CMVD Subtypes by Sex 
Despite these similarities, the frequency of female CMVD patients when compared to 
those in both referral categories are worth mentioning. Consistent with previous literature (60), 
the majority of the CMVD sample is female (60.1%), whereas these proportions are almost 
reversed in both the epicardial and unconfirmed groups, with approximately one-third of their 
cohorts being female.  As women with coronary microvascular dysfunction are often menopausal 
or approaching menopause when diagnosed with CMVD (61), hormonal differences are likely to 
play an important role. While research surrounding these differences is still in its infancy, a few 
pathophysiological theories suggest differences, such as decreased estrogen levels (62), which 
has been shown to have a strong protective effect on the development of cardiovascular diseases 
(63), and tends to favor factors that increase the ratio of vasodilation over vasoconstriction (64). 
It is therefore hypothesized that after menopause, there is a large decrease in estrogen levels 
amongst women, increasing their likelihood of developing coronary microvascular dysfunction 
(64). According to results from various cross-sectional studies, the median age at menopause for 
white women, similar to our cohort, is between 50 to 52 years of age (65). Despite this, the mean 
age difference between males and females with CMVD in our study do not vary greatly (~1.3 
years in age).  
In an effort to obtain a better representation of the CMVD patient demographics, our 
study sorted microvascular patients based on suspected syndrome X or syndrome Y 
characteristics. Many with microvascular dysfunction are oftentimes classified as “Syndrome X” 
cases; clinical features typically include angina with normal coronary arteries. “Syndrome Y”, or 
“coronary slow flow phenomenon”, possesses similar characteristics, except for the added 
dysfunction of elevated arterial resistance, as demonstrated by a slow progression of the dye 
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injected into the coronary vasculature upon coronary angiography (66). Both syndromes are most 
commonly associated with impaired microvascular function and are typically seen as subgroups 
of CMVD (67). This is seen in our findings, as both syndrome X and syndrome Y were 
significantly associated with the CMVD study participants. Our data has shown an almost equal 
divide between both suspected subgroups in CMVD participants, with no particular syndrome 
taking a lead. Additional differences are often seen on a population level between syndrome 
subgroups; those with syndrome X are more likely to be older menopausal women, whereas 
those with suspected syndrome Y have typically been younger male smokers (68).  These trends 
were not seen in our data, considering the frequency of males vs females were almost identical 
between the groups, displaying no real difference between the overall general population of those 
with syndrome x and syndrome y within CMVD groups.  
 
Risk Factors amongst All Referral Groups 
Metabolic Factors 
 Consistent with previous literature (69), many metabolic risk factors, such as triglyceride 
levels, HDL, LDL levels and waist circumference were elevated in all coronary referral groups. 
Similarly, high rates of MetS were common in both macrovascular and microvascular patients in 
our study. Past research has also found that shared risk factors for both CMVD and traditional 
cardiovascular diseases include smoking, diabetes, age, hypertension, and hyperlipidemia (70).  
However, in the present analysis, waist circumference, and LDL levels were all higher in in 
CMVD patients, whereas triglycerides and HDL were all lower when compared to epicardial 
patients. Interestingly, recent literature suggests that systemic inflammation plays a large role in 
the development of coronary artery disease and may be an even larger risk factor in those with 
 23 
CMVD (51).  C-reactive protein (CRP), also found to have a significant association to coronary 
referral groups, is a traditional marker of inflammation that has been shown to be heavily tied to 
triglycerides, obesity, blood pressure, and fasting glucose (71). It is for this reason that CRP 
levels have been reported as being a reflective marker of cardiac health, as it encompasses many 
of the risk factors present in those with CAD. The presence of CRP is not only a marker of poor 
coronary health, but is indicative of reduced coronary flow, a hallmark adaptation of patients 
with CMVD.  
 
Movement Behaviours 
Sleep Quality and Quantity 
When assessing our primary outcome variables, sleep quality and quantity were found to 
have significant associations with referral category in our analysis. To be more precise, it was 
observed that a little under a quarter of all CMVD participants were experiencing shorter sleep 
periods at night (<5 hours per night), which is almost double the amount of short sleepers as the 
epicardial or unconfirmed referral groups. More specifically, more than half of those with 
suspected CMVD answered that they did not wake up feeling rested, whereas the reverse can be 
said for those in the epicardial group, as almost 60% of them revealed that they did waking up 
feeling rested. To date, very few studies have examined the relationship between sleep and 
coronary microvascular dysfunction; however, in those that have one of the most common sleep 
disturbances, obstructive sleep apnea (OSA) - has been linked to increased levels of C-reactive 
protein levels, as well as elevated apnoea-hypopnoea index (AHI) values - of which both are 
related to decreased coronary flow reserve, ultimately impairing coronary microvasculature (72), 
leading to symptoms of coronary microvascular dysfunction. Some of the most common 
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complaints of those with OSA are that of fatigue, loud snoring, and choking (73). When 
observing the frequency at which our participants felt fatigued during the day, almost 78% of 
those in the CMVD group had answered ‘yes’ to the question, a striking difference between the 
two other referral groups (Epicardial: 59.8 % vs Unconfirmed: 53.1%). The results of the STOP-
BANG questionnaire, a validated screening tool for OSA (74), did not show significance 
between the three groups. Approximately a quarter of both CMVD and Epicardial participants 
were both placed in the high-risk groups, whereas an additional 15% of epicardial and CMVD 
patients were classified as intermediate-risk.  
Finally, results of the logistic regression analyses revealed that the most consistent 
differences found amongst CMVD patients were noticed in sleep quality. Participants that felt 
they were not well rested were almost 95% more likely to have a CMVD diagnosis in the 
unadjusted model. Additionally, participants that felt as though they were fatigued during the day 
were almost 2.4 times more likely to have coronary microvascular dysfunction than a traditional 
epicardial case in the same model. These numbers remained significant after adjustment for age 
and sex, but not in fully adjusted models. Increased risk of obstructive sleep apnea risk, which 
was measured using the STOP-BANG criteria, was also found to be more frequent amongst 
CMVD patients with obesity, confirming a substantial relationship between sleep quality and 
CMVD outcome.  
 
Physical Activity  
Interestingly, physical activity patterns did not materially differ across diagnostic groups, 
despite our initial hypothesis. More specifically, there were no significant differences between 
referral groups amongst those who did (vs did not) meet current physical activity guidelines, 
 25 
regardless of statistical adjustment. This may be explained in part by the high level of inactivity 
observed in all groups, as supported by earlier studies suggesting few differences between 
physical activity trends and potential risk factors patients with CMVD and those with traditional, 
epicardial disease (71). 
 
Movement behaviours amongst CMVD participants 
When observing sleep and sedentary behaviour within CMVD patients exclusively, 
patients who were also classified as obese tended to have significantly worse sleep and activity 
patterns than those who were non-obese. Our analysis revealed significant associations between 
sitting time in participants with CMVD that were obese vs normal and overweight groups. 
Similarly, a notable association was found between obese and normal weight CMVD participants 
and STOP-BANG risk levels. Multiple studies have made obesity a key focus of CMVD (75, 76) 
as impaired microvascular dysfunction is commonly observed in individuals with (vs without) 
obesity (32).  Although it is well understood that obesity is a significant risk factor in the 
development of CMVD, the exact role of obesity in CMVD functioning remains poorly 
understood. It has been proposed that some of the pathophysiological mechanisms through which 
obesity affects coronary microvascular dysfunction is through adipocyte-derived factors that 
contribute to vascular oxidative stress, increased neurohormonal activity as well as systemic 
inflammation (32). In line with this, our study confirmed a positive association between CRP, an 
acute inflammatory marker and both BMI and coronary microvascular dysfunction. As seen in 
our analysis, those with high risk CRP levels, when compared to low risk, are almost 2.5 times 
more likely of developing CMVD when compared to traditional epicardial patients. Additionally, 
patients classified as “obese” were 31.7% more likely to have CMVD when compared to those in 
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the normal BMI category.         
 
7.1  Limitations 
This study had several important limitations to note. The first limitation was that our 
participant pool was relatively homogenous, and participant data was collected upon initial visit. 
As a result, patient diagnoses are all “suspected” cases (of CMVD), which were undergoing 
further clinical investigation (and could change over follow-up). Furthermore, patients were 
sorted into referral categories based on a variety of symptoms and tests completed, which may 
vary from patient to patient. Preliminary diagnoses were a result of the cardiologist on site, and 
not through a standard test. This increases uncertainty and variability within our sample. Due to 
the uniqueness of this clinic sample and the exploratory nature of this work, a final analytic 
sample was not held constant through all analyses, and not all sections of the questionnaires were 
completed by each patient. Additionally, information on patient medications were not accounted 
for, which may ultimately impact on the interpretation of metabolic profile data. As this is a 
cross-sectional study, a significant limitation to consider is that of a lack of temporal evidence 
between exposure and outcome variables as they are studied and assessed at the same time.  
Lastly, because almost half of the data used in this study was self-reported, we cannot exclude 
the possibility of recall and healthy responder bias on the observed relationships.  
 
7.2  Conclusion and Future Directions 
It is important to note that despite differences in the risk factors found between CMVD 
and Epicardial patients, the majority of variables examined showed no overt difference between 
the referral groups. Further research, however, is necessary after definitive diagnosis and follow-
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up, to either establish or refute the presence of movement behavior differences, as well as to 
examine longer-term outcomes (e.g. healthcare utilization, recurrent coronary events, and 
mortality). 
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Figure 1: Flow Chart of final participant study size  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Sample 
(n=594)
Patients Lost to Follow-Up
(n=158)
Eligible for Responses 
(n=436)
Suspected Microvascular 
Dysfunction
(n=208)
Obstructive Epicardial CAD
(n=170)
Other
(n=58)
Cardiac abnormalities of unknown origin, 
symptoms pending further investigation
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Table 1: Frequency table of descriptive characteristics by referral category. 
  
CMVD 
 
Epicardial 
 
Unconfirmed 
 
Total 
 
Sex *** 
Male 
Female 
Ethnicity * 
White 
South Asian 
Asian 
African-American 
Aboriginal 
Other 
Employment Status  
Full Time  
Part Time 
Not Looking For Work 
On Disability 
Unemployed 
Retired 
Caregiver 
Marital Status * 
Married 
Single 
Divorced 
Widow(er) 
Domestic Partner 
Smoking History 
Current 
Never 
Previous smoker 
Drinks per day 
Never 
Less than One 
One 
Two to Three 
Three to Five 
6 or more 
Cannabis Use 
Never 
Rarely 
Regularly 
Every week, not every day 
Rather not say 
 
n=208 
83 (39.9%) 
125 (60.1%) 
n=205 
175 (85.4%) 
3 (1.5%) 
8 (3.9%) 
1 (0.5%) 
4 (2.0%) 
14 (6.8%) 
n=205 
84 (41.0%) 
13 (6.3%) 
1 (0.5%) 
32 (15.6%) 
7 (3.4%) 
62 (30.2%) 
6 (2.9%) 
n=205 
138 (67.7%) 
24 (11.7%) 
6 (2.9%) 
16 (7.8%) 
21 (10.2%) 
n=204 
23 (11.3%) 
90 (44.1%) 
91 (44.6%) 
n=204 
74 (36.3%) 
88 (43.1%) 
21 (10.3%) 
16 (7.8%) 
3 (1.5%) 
2 (1.0%) 
n=204 
183 (89.7%) 
13 (6.4%) 
2 (1.0%) 
5 (2.5%) 
1 (0.5%) 
 
n=170 
117 (68.8%) 
53 (31.2%) 
n=167 
130 (77.8%) 
13 (7.8%) 
13 (7.8%) 
0 (0.0%) 
1 (0.6%) 
10 (6.0%) 
n=167 
77 (46.1%) 
11 (6.6%) 
4 (2.4%) 
13 (7.8%) 
6 (3.6%) 
56 (33.5%) 
0 (0.0%) 
n=167 
121 (72.5%) 
22 (13.2%) 
10 (6.0%) 
7 (4.2%) 
7 (4.2%) 
n=167 
12 (7.2%) 
64 (38.3%) 
91 (54.5%) 
n=167 
61 (36.5%) 
66 (39.5%) 
26 (15.6%) 
12 (7.2%) 
2 (1.2%) 
0 (0.0%) 
n=167 
143 (85.6%) 
9 (5.4%) 
5 (3.0%) 
7 (4.2%) 
3 (1.8%) 
 
n=57 
38 (66.7%) 
19 (33.3%) 
n=49 
42 (85.7%) 
0 (0.0%) 
5 (10.2%) 
0 (0.0%) 
0 (0.0%) 
2 (4.1%) 
n=49 
21 (42.9%) 
2 (4.1%) 
1 (2.0%) 
6 (12.2%) 
1 (2.0%) 
18 (36.7%) 
0 (0.0%) 
n=49 
40 (81.6%) 
3 (6.1%) 
2 (4.1%) 
3 (6.1%) 
1 (2.0%) 
n=49 
4 (8.2%) 
20 (40.8%) 
25 (51.0%) 
n=49 
20 (40.8%) 
18 (36.7%) 
9 (18.4%) 
2 (4.1%) 
0 (0.0%) 
0 (0.0%) 
n=49 
42 (85.7%) 
4 (8.2%) 
2 (4.1%) 
0 (0.0%) 
1 (2.0%) 
 
n=435 
238 (54.7%) 
197 (45.3%) 
n=421 
347 (82.4%) 
16 (3.8%) 
26 (6.2%) 
1 (0.2%) 
5 (1.2%) 
26 (6.2%) 
n=421 
182 (43.2%) 
26 (6.2%) 
6 (1.4%) 
51 (12.1%) 
14 (3.3%) 
136 (32.3%) 
6 (1.4%) 
n=421 
299 (71.0%) 
49 (11.6%) 
18 (4.3%) 
26 (6.2%) 
29 (6.9%) 
n=420 
39 (9.3%) 
174 (41.4%) 
207 (49.3%) 
n=420 
155 (36.9%) 
172 (41.0%) 
56 (13.3%) 
30 (7.1%) 
5 (1.2%) 
2 (0.5%) 
n=420 
368 (87.6%) 
26 (6.2%) 
9 (2.1%) 
12 (2.9%) 
5 (1.2%) 
Differences between the 3 groups were analyzed using χ². *P value for group differences <0.05.  
**p value for group differences <0.01 *** p value for differences <0.001 
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Table 2: Frequency of metabolic and clinical characteristics by suspected diagnosis. 
 
Age (x̅ ± SD) * 
Total 
Male 
Female 
Anthropometric (x̅ ± SD) 
BMI (kg/m²) 
Underweight/Normal Weight 
Overweight 
Obese 
Waist Circumference (cm) 
High WC (>102 M, >88 F) * 
MetS Risk Factors (%) 
0 
1 
2 
3 
4+ ** 
5 
Metabolic Factors (x̅ ± SD) 
Triglycerides * 
HDL * 
Fasting Glucose 
Systolic Blood Pressure 
Diastolic Blood Pressure 
LDL *** 
CRP * 
Triglycerides 
Levels > 2.2 mmol/L 
HDL  
M <1.04, F <1.29 mmol/L 
Blood Pressure   
≥ 130/85 
< 130/85 
Metabolic Syndrome 
> 3 out of 5 criteria 
< 3 out of 5 criteria 
CRP Level ** 
Low < 1.0 mg/L 
Intermediate 1.0 – 2.9 mg/L  
High > 3.0 mg/L 
CMVD 
n=208 
58.5 ± 14.5 a 
59.3 ± 14.3 ab 
58.0 ± 14.6 ab 
n=207 
27.8 ± 5.5 
22.0 ± 3.5 
27.5 ± 1.4 
34.5 ± 3.6 
98.4 ±16.4 
106.6 ± 12.5 a 
n=149 
29 (19.5%) 
34 (22.8%) 
44 (29.5%) 
24 (16.1%) 
17 (11.4%) 
1 (0.7%) 
n=208 
1.2 ± 0.6 a 
1.3 ± 0.4 a 
5.9 ± 1.2 
122.2 ± 18.2 
74.8 ± 10.7 
1.5 ± 0.7 ab 
2.7 ± 3.3 ab 
n=155 
25 (16.1%) 
n=153 
43 (28.1%) 
n=207 
25 (12.1%) 
182 (87.9%) 
n=149 
42 (28.0%) 
107 (72.0%) 
n=145 
54 (37.2%) 
49 (33.8%) 
42 (29.0%) 
Epicardial 
n=170 
62.0 ± 10.8  
61.5 ± 11.0 
63.2 ± 10.5 
n=170 
28.6 ± 6.00 
22.3 ± 2.00 
27.4 ± 1.4 
35.5 ± 5.30 
97.7 ± 18.7 
107.7 ± 10.7 
n=118 
24 (33.3%) 
31 (26.3%) 
37 (31.4%) 
24 (33.3%) 
2 (1.7%) 
0 (0.0%) 
n=170 
 1.6 ± 1.1 
1.5 ± 0.8 
6.0 ± 1.9 
124.0 ± 17.7 
76.1 ± 10.0 
2.2 ± 0.9 
2.7 ± 6.0 
n=125 
10 (29.4%) 
n=124 
42 (33.9%) 
n=169 
18 (8.7%) 
151 (91.3%) 
n=118 
26 (22.0%) 
92 (78.0%) 
n=116 
58 (50%) 
37 (32%) 
21 (18.1%) 
Unconfirmed 
n=57 
59.3 ± 14.6 
61.6 ± 14.2 
55.1 ± 14.7 
n=57 
26.9 ± 5.4 
21.1 ± 4.9 
27.2 ±1.5 
33.1 ± 3.4 
92.8 ± 23.9 
99.0 ± 29.4 
n=30 
8 (2.7%) 
9 (30.0%) 
7 (23.3%) 
5 (16.7%) 
1 (3.3%) 
0 (0.0%) 
n=57 
1.5 ± 1.0 
1.4 ± 0.7 
5.9 ± 1.6 
123.1 ± 17.9 
75.5 ± 10.4 
1.9 ± 0.9 
2.0 ± 2.0 
n=34 
5 (14.7%) 
n=34 
8 (23.5%) 
n=56 
5 (2.4%) 
51 (97.6%) 
n=30 
6 (20.0%) 
24 (80.0%) 
n=29 
7 (24.1%) 
17 (58.6%) 
5 (17.2%) 
Total 
n=435 
60.1 ± 13.3 
60.8 ± 12.7 
59.1 ± 13.8 
n=434 
28.0 ± 5.7 
22.0 ± 3.2 
27.4 ± 1.4 
34.8 ± 4.6 
97.3 ± 18.7 
106.1 ± 15.1 
n=297 
61 (20.5%) 
74 (25.0%) 
88 (30.0%) 
53 (17.8%) 
20 (6.7%) 
1 (0.3%) 
n=435 
1.5 ± 1.0 
1.4 ± 0.7 
5.9 ± 1.6 
123.1 ± 17.9 
75.5 ± 10.4 
1.9 ± 0.9 
2.7 ± 6.0 
n=314 
40 (12.7%) 
n=311 
9 (2.9%) 
n=432 
48 (11.0%) 
384 (88.3%) 
n=297 
74 (24.9%) 
223 (75.1%) 
n=290 
119 (41.0%) 
103 (35.5%) 
68 (23.5%) 
Differences between groups: χ² for categorical variables, ANOVA for continuous variables. *P 
value for group differences <0.05. ** p <0.01 *** p <0.001.a significance between CMVD and 
epicardial group ab significance between all groups  
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Table 3: Frequency of patient-reported health outcomes by suspected diagnosis. 
 
  
CMVD 
 
Epicardial 
 
Unconfirmed 
 
Total 
 
Patient Reported Outcomes (%) 
MI *** 
CABG 
AFIB 
Clots 
TIA 
Claudication 
FHPHD *** 
Hypertension 
Diabetes 
Hyperlipidemia 
Psoriasis 
Autoimmune 
Osteoarthritis * 
Gastroesophageal * 
Anxiety ** 
MAD syndrome * 
COPD 
Cancer 
Asthma 
Liver 
CFS 
 
Self-rated Health (x̅ ± SD) 
Physical QOL *** 
Psychological QOL * 
 
n=208 
82 (39.4%) 
1 (0.48%) 
14 (6.7%) 
3 (1.4%) 
4 (1.9%) 
0 (0.0%) 
79 (38.0%) 
108 
(51.9%) 
32 (15.4%) 
98 (47.1%) 
7 (3.4%) 
8 (3.8%) 
9 (4.3%) 
37 (17.8%) 
34 (16.3%) 
45 (21.6%) 
13 (6.3%) 
13 (6.3%) 
15 (7.2%) 
3 (1.4%) 
3 (1.4%) 
 
n=62 
3.5 ±1.1 ab 
3.2± 1.0 a 
 
n=170 
126 (74.1%) 
5 (2.9%) 
11 (6.5%) 
4 (2.4%) 
2 (1.2%) 
1 (0.6%) 
40 (23.5%) 
83 (48.8%) 
42 (24.7%) 
77 (45.3%) 
3 (1.2%) 
2 (1.2%) 
6 (3.5%) 
16 (9.4%) 
10 (5.8%) 
19 (11.2%) 
4 (2.4%) 
7 (4.1%) 
8 (4.7%) 
3 (1.8%) 
0 (0.0%) 
 
n=18 
3.0 ± 1.2 
2.9 ± 1.0 
 
n=57 
34 (59.6%) 
0 (0.0%) 
2 (3.5%) 
1 (1.8%) 
1 (1.8%) 
0 (0.0%) 
7 (12.3%) 
22 (39.0%) 
5 (8.8%) 
18 (31.6%) 
1 (1.8%) 
1 (1.8%) 
2 (3.5%) 
4 (7.0%) 
5 (8.8%) 
7 (12.3%) 
2 (3.5%) 
3 (5.3%) 
1 (1.8%) 
0 (0.0%) 
0 (0.0%) 
 
n=2 
3.6 ± 0.7 
3.3 ± 0.4 
 
n=435 
242 (55.6%) 
6 (1.4%) 
27 (6.2%) 
8 (1.8%) 
7 (1.6%) 
1 (0.2%) 
126 (29.0%) 
213 (49.0%) 
79 (18.2%) 
193 (44.4%) 
11 (2.5%) 
11 (2.5%) 
28 (6.4%) 
57 (13.1%) 
49 (11.3%) 
71 (16.3%) 
19 (4.4%) 
23 (5.3%) 
24 (5.5%) 
6 (1.4%) 
3 (0.7%) 
 
n=82 
3.6 ± 0.7 
3.3 ± 0.4 
 
Differences between the 3 groups were analyzed using χ². *P value for group differences <0.05. 
**p value for group differences <0.01 *** p value for differences <0.001. a significance between 
CMVD and epicardial group.  ab significance between CMVD group and ‘Unconfirmed’ group 
TG, triglycerides; BP, Blood Pressure; MI, Myocardial Ischemia; AFIB, Atrial Fibrillation, TIA, 
transient ischemic attack;  
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Figure 2: Bar graph of the number of CMVD (%) cases of syndrome x, syndrome y and ‘other’ 
by sex. Differences between the 3 groups were analyzed using χ². 
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Table 4: Frequency of movement behaviours by suspected diagnosis 
 
  
CMVD 
 
Epicardial 
 
Unconfirmed 
 
Total 
Physical Activity Level 
Meeting Guidelines (≥ 
150mins/week) 
Not Meeting Guidelines (< 
150mins/week) 
Sitting Time 
<1/4  
 1/4 
 1/2 
 3/4 
 Almost all day 
Online Screen Time Per Day 
 <2  
   2 
   3 
   4 
   5 
   6+ 
STOP-BANG Score 
Low Risk 
Intermediate Risk 
High Risk 
Hours of sleep per night * 
< 5 
   6 
   7 
   8 
   9+ 
Self-perceived Sleep Quality * 
Wake up Rested ** 
Snore Loudly 
Fatigued during day *** 
Stop breathing during sleep 
n=197 
102 (51.8%) 
 
95 (48.2%) 
 
n=197 
47 (23.9%) 
41 (20.8%) 
53 (26.9%) 
45 (22.8%) 
11 (5.6%) 
n=197 
51 (25.9%) 
32 (16.2%) 
33 (16.8%) 
26 (13.2%) 
22 (11.2%) 
33 (16.8%) 
n=209 
77 (36.8%) 
80 (38.3%) 
52 (24.9%) 
n=203 
41 (20.2%) 
46 (22.7%) 
67 (33.0%) 
37 (18.2%) 
12 (5.9%) 
n=203 
83 (40.9%) 
69 (34.2%) 
157 (77.7%) 
40 (19.8%) 
n=161 
89 (63.4%) 
 
72 (44.7%) 
 
n=161 
37 (23.0%) 
40 (24.8%) 
43 (26.7%) 
36 (22.4%) 
5 (3.1%) 
n=161 
37 (23.0%) 
27 (16.8%) 
31 (19.3%) 
19 (11.8%) 
13 (8.1%) 
34 (21.1%) 
n=170 
45 (26.5%) 
81 (47.6%) 
44 (25.9%) 
n=164 
19 (11.6%) 
53 (32.3%) 
63 (38.4%) 
23 (14.0%) 
6 (3.7%) 
n=164 
94 (57.3%) 
58 (35.4%) 
98 (59.8%) 
36 (22.0%) 
n=49 
28 (57.1%) 
 
21 (42.9%) 
 
n=49  
10 (20.4%) 
16 (32.7%) 
16 (32.7%) 
5 (10.2%) 
2 (4.1%) 
n=49 
14 (28.6%) 
8 (16.3%) 
6 (12.2%) 
11 (22.4%) 
4 (8.2%) 
6 (12.2%) 
n=57 
24 (42.1%) 
24 (42.1%) 
9 (15.8%) 
n=49 
5 (10.2%) 
8 (16.3%) 
18 (36.7%) 
13 (26.5%) 
5 (10.2%) 
n=49 
22 (44.9%) 
13 (26.5%) 
26 (53.1%) 
13 (26.5%) 
n=407 
219 (53.8%) 
 
188 (46.2%) 
 
n=407  
94 (23.1%) 
97 (23.8%) 
112 (27.5%)  
86 (21.1%) 
18 (4.4%) 
n=407 
102 (25.1%) 
67 (16.5%) 
70 (17.2%) 
56 (13.8%) 
39 (9.6%) 
73 (17.9%) 
n=436 
146 (33.5%) 
185 (42.4%) 
105 (24.1%) 
n=416 
65 (15.6%) 
107 (25.7%) 
148 (35.6%) 
73 (17.5%) 
23 (5.5%) 
n=416 
199 (47.8%) 
140 (33.7%) 
281 (67.7%) 
89 (21.4%) 
Differences between the 3 groups were analyzed using χ². *P value for group differences <0.05. 
**p value for group differences <0.01 *** p value for differences <0.00. PA, physical activity  
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Table 5: Frequency of sitting time, physical activity, and sleep quality and quantity amongst 
CMVD-BMI groups 
 
  
Under/Normal 
Weight 
 
Overweight 
 
Obese 
 
 
Sitting Time a 
Low Sitting Time (Less than 3/4 of 
day) 
Increased Sitting Time (3/4 of day or 
more) 
   
Physical Activity Level  
< 150 mins MVPA 
≥ 150 mins MVPA 
 
Hours of Sleep per night 
Inadequate Sleep (6 hours or less)  
Adequate Sleep (7 hours or more) 
  
STOP-BANG Score ab 
Low Sleep Apnea Risk  
Intermediate Sleep Apnea Risk 
High Sleep Apnea Risk  
 
 
 
n=49 
38 (77.6%) 
11 (22.4%) 
 
n=49 
17 (34.7%) 
32 (65.3%) 
 
n=50 
20 (40.0%) 
30 (60.0%) 
 
 
n=52 
28 (54.0%) 
22 (42.3%) 
2 (3.8%) 
 
 
n=88 
65 (73.9%) 
23 (26.1%) 
 
n=88 
44 (50.0%) 
44 (50.0%) 
 
n=91 
39 (42.9%) 
52 (57.1%) 
 
 
n=92 
36 (39.1%) 
37 (40.2%) 
19 (20.7%) 
 
 
n=60 
38 (63.3%) 
22 (36.7%) 
 
n=60 
34 (56.7%) 
26 (43.3%) 
 
n=62 
28 (45.2%) 
34 (54.8%) 
 
 
n=63 a 
11 (17.5%) 
21 (33.3%) 
31 (49.2%) 
 
Differences between the 3 groups were analyzed using χ². *P value for group differences <0.05. 
a significance between group category and obese weight BMI group b significance between 
group category and normal weight BMI group 
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Table 6: Unadjusted and adjusted ORs movement behaviour variables by suspected diagnosis 
 
Comorbidities 
 
BMI 
Overweight vs 
Underweight/Normal 
Obese vs 
Underweight/Normal * 
MetS 
MetS vs No MetS 
STOP-BANG 
Intermediate vs Low 
High vs Low 
Exercise Guidelines (≥ 
150mins/week) 
High Risk vs Low Risk 
Sitting Time 
High Risk vs Low Risk 
Sleep Quantity 
Ideal vs Poor  
† Self-perceived Sleep 
Quality 
Not Rested * 
Snore Loudly 
Fatigued during day * 
Stop breathing during 
CRP Levels 
Intermediate vs Low Risk 
High vs Low Risk * 
Sex 
Female vs Male * 
Model 1 
 
 
1.20 (0.73 – 1.96) 
 
 
1.32 (0.77 – 2.27) 
 
1.39 (0.79 – 2.44) 
 
0.58 (0.36 – 0.93) 
0.69 (0.40 –1.19) 
 
 
1.15 (0.76 – 1.75) 
 
1.16 (0.73 – 1.86) 
 
0.95 (0.63 – 1.44) 
 
 
1.94 (1.28 – 2.95) 
0.95 (0.62 – 1.46) 
2.35 (1.49 – 3.70) 
0.88 (0.53 – 1.46) 
 
1.48 (0.84 – 2.61) 
2.36 (1.23 – 4.52) 
 
3.33 (2.17 – 5.10) 
Model 2 
 
 
1.58 (0.93 – 2.70) 
 
 
1.62 (0.91 – 2.90) 
 
1.79 (0.98 – 3.28) 
 
0.95 (0.56 – 1.62) 
1.54 (0.82 – 2.90) 
 
 
1.13 (0.73 - 1.76) 
 
1.08 (0.66 – 1.78) 
 
1.02 (0.66 – 1.58) 
 
 
1.47 (0.94 – 2.30) 
1.20 (0.76 – 1.91) 
1.96 (1.21 – 3.17) 
1.08 (0.63 – 1.84) 
 
1.38 (0.76 – 2.50) 
2.07 (1.05 – 4.11) 
 
3.32 (2.16 – 5.11) 
Model 3 
 
 
0.62 (0.32 –1.18) 
 
 
0.28 (0.12 – 0.65) 
 
1.523 (0.77 – 3.03) 
 
14.90 (2.28 – 10.57) 
8.10 (2.54 – 25.91) 
 
 
1.11 (0.63 – 1.96) 
 
0.98 (0.59 – 1.66) 
 
0.85 (0.48 – 1.50) 
 
 
1.37 (0.74 – 2.55) 
1.81 (0.88 – 3.75) 
2.27 (1.06 – 4.88) 
1.21 (0.52 – 2.79) 
 
1.38 (0.76 – 2.50) 
2.09 (1.05 – 4.14) 
 
2.62 (1.32 
 
*OR – Odds Ratio, CI – Confidence Interval. CMVD groups were used as reference group.  
† Reference group include all those who answered “no.” 
Model 1: Unadjusted;  
Model 2: Adjusted for age and sex;  
Model 3: Adjusted for age, sex, BMI, STOP-BANG Score, Exercise, Sitting Time, Self-
Perceived Sleep Quality, CRP levels. 
 
 
 
 
 
 
 
 43 
Appendix A: Self-Reported Questionnaire 
Name: 
 
Date Of Birth 
 
Sex: Male female  other 
 
Marital Status: 
 
Single married domestic partner divorced widow(er) 
 
Race: 
 
African-American Asian Caucasian Native American  South Asian other 
 
Education: 
 
Some education High school Some College/university College/University degree 
 Post graduate (ie masters or phd)  professional (ie law, medicine) 
 
Employment status: 
 
Full time Part time retired  unemployed on disability 
 
Tobacco use? 
   
I never smoked I currently smoke I smoked in the past but not now 
 
If you currently smoke, how much do you smoke?: 
 
Never rarely  every week but not every day  regularly but < 1 pack/day 1-2 packs per 
day  >2 packs/day 
 
How many alcoholic beverages do you consume per day (on average) 
 
Never less than one one 2-3 3-5 6 or more 
 
How often do you consume or smoke marijuana products 
 
Never  rarely every week but not every day regularly  I’d rather not say 
 
Morgen Sleep Questionaire 
 
How many hours of sleep do you usually get per 24 hour period (ie every day)? 
5 hrs or less 6 hours 7 hours 8hours 9hrs or more 
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When you wake up in the morning, do you usually rise feeling rested? 
Yes no 
 
 
STOP score 
 
1. Do you snore loudly (louder than talking or loud enough to be heard through closed doors)? 
 
Yes no 
 
2. Do you often feel tired, fatigued or sleep during the daytime? 
 
Yes no 
 
3. Has anyone observed you stop breathing during your sleep? 
 
Yes no 
 
4. Do you have or are you being treated for high blood pressure 
 
Yes no 
 
(Score /4) 
 
*note “BANG” part of score will be done by NP 
BANG components = BMI >35, Age >50, Neck circumference > 40 cm, Gender = male 
 
Hi risk 5-7, intermediate risk 3-4 
 
Restless Legs Syndrome Screen: 
 
Do you have, or have you had recurrent uncomfortable feelings or sensations in your legs while 
you are sitting or lying down 
 
Yes no 
 
Do you, or have you had, a recurrent need or urge to move your legs while you were sitting or 
lying down? 
 
Yes no 
 
Score:  /2 
 
Anxiety Questionaire: 
For the following questions, please answer on a scale of 0-4 with 0 = never to 4 = always 
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Do you feel tensed up? 
0 (never) 1 2 3 4 (always) 
Do you worry a lot? 
0 1 2 3 4 
Do you have panic attacks? 
0 1 2 3 4 
Do you feel something awful is about to happen? 
0 1 2 3 4 
 
Score: /16 
 
Depression Questionaire: 
For the following questions please answer on a scale of 0-4 with 0= always and 4 = never 
** please note that the scale is reversed compared to above** 
 
 
Do you take as much interest in things as you used to? 
0 (always) 1 2 3 4(never) 
Do you laugh as readily?  
0 (always) 1 2 3 4(never) 
Do you feel cheerful? 
0 (always) 1 2 3 4(never) 
Do you feel generally optimistic about the future? 
0 (always) 1 2 3 4(never) 
 
Score : /16 
 
Physical Activity:  
 
Vigorous Exercise:  
Vigorous activities cause large increased in breathing or heart rate.  
Examples include jogging aerobics, heavy yard work etc. 
 
How many times per week do you do these vigorous activities for at least 10 minutes at a time? 
 
0 1 2 3 4 5 6 7 
 
On days when you do vigorous activities, how much total time per day do you spend on these 
activities? 
 
10 minutes 20 minutes 30 minutes 40 minutes 50 minutes 60 minutes or more 
 
Database Variable = # times per week x time spent 
 
Per week do you perform at least 75 minutes of vigorous activity?  Yes no   
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Moderate Exercise:  
Moderate activities cause small increases in breathing or heart rate.  
Examples include brisk walking, bicycling, vacuuming gardening etc.  
 
How many times per week do you do these moderate activities for at least 10 minutes at a time? 
 
0 1 2 3 4 5 6 7 
 
On days when you do moderate intensity activities, how much total time per day do you spend on 
these activities? 
 
10 minutes 20 minutes 30 minutes 40 minutes 50 minutes 60 minutes or more 
 
Database variable = # times per week X time spent 
 
Per week do you perform at least 150 minutes of moderate activity?  Yes no 
 
Database variable = vigorous + moderate exercise time 
 
Sedentary Time: 
In a typical day, of your waking hours, including work, how much time do you spend sitting? 
 
Less than ¼ ¼ ½ ¾ almost all 
 
In a typical day, how many hours do you spend on the computer and/or playing video games 
and/or watching television and/or reading: 
 
< 2hrs  2 hours 3 hours 4 hours  5  hours 6hrs or more  
 
Attitudes towards exercise and cardiac rehab: 
 
You may be prescribed cardiac rehabilitation, including an exercise program,  for your cardiac 
problem 
 
For the next series of questions, circle a number from 1 to 7.  
1- Very Strongly Disagree     2- Strongly Disagree   3. Disagree                                                                               
4- Neither agree nor disagree 5 – Agree 6. Strongly agree              
7 – Very Strongly Agree 
 
1. My recovery may be hindered if I do not complete exercise-based cardiac rehab 
2. In order to prevent more heart problems, exercise-based cardiac rehab is essential 
3. The way to prevent my heart problem from worsening is to follow my exercise-based  rehab 
program 
4. A successful and lasting recovery may not be possible if I do not complete my exercise-based 
cardiac rehab.  
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5. I make it more likely to have recurrent heart problems if I do not complete exercise-based 
cardiac rehab. 
 
6. The exercise-based cardiac rehab program designed for me will ensure my recovery 
7. Completion of my exercise-based cardiac rehab will make me live longer 
8. Following the advice the I have been given will have a very large impact on how quickly I 
recover 
9. I have absolute faith in the effectiveness of the exercise-based rehab program 
 
10. I am capable of completing all aspects of my exercise-based cardiac rehab program 
11. I consider myself able to stick to my exercise-based rehab program even if it includes 
activities that I do not enjoy 
12. I will have no serious difficulty in following the instructions of my exercise-bsaed rehab 
program 
13. I believe that I will stick with my exercise-based rehab program 
 
14. As medical conditions go, mine is serious 
15. I see my cardiac problem as a serious threat to my quality  of life 
16. I fear that my cardiac problem with affect my long-term health 
17. My cardiac problem is too serious to not follow medical advice 
 
 
Susceptibility score: add Q’s 1-5 
Severity score: add Q’s 14-17 
Self-efficacy; Add Q’s 10-13 
Treatment efficacy: Add Q’s 6-9 
 
Quality of Life: SF-12 Questionnaire  
 
1. In general would you way your health is: 
 
excellent  very good  good fair poor 
 
2. The following items are about activities you might do during a typical day. Does your health 
now limit you in these activities? If so, how much? 
 
a) Moderate activities such as moving a table, pushing a vacuum cleaner, bowling or playing 
golf: 
 
Yes limited a lot  yes limited a little  no not limited at all 
 
b) climbing several flights of stairs 
 
Yes limited a lot  yes limited a little  no not limited at all 
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3. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health 
 
a) accomplished less than you would like 
yes  no 
 
b) were limited in the kind of work or other activities 
yes  no 
 
4. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of emotional problem (such as feeling depressed or anxious)? 
 
a) accomplished less than you would like 
yes  no 
 
b) didn’t do work or other activities as carefully as usual 
yes  no 
 
5. During the past 4 weeks, how much did pain interfere with your normal work ? 
 
Not at all  a little bit  moderately  quite a bit extremely 
 
These questions are about how you felt and how things have been with you during the past 4 
weeks. For each question, please give the one answer that comes closest to the way you have 
been feeling.  
 
How much of the time during the past 4 weeks: 
 
a) have you felt calm and peaceful? 
 
all of the time,   most of the time,  a good bit of the time,    some 
of the time,  a little bit of the time,  none of the time 
 
b) did you have a lot of energy? 
 
all of the time,  most of the time,  a good bit of the time,  some of the time, 
 a little bit of the time,  none of the time 
 
c) have you felt downhearted and blue? 
 
all of the time,  most of the time,  a good bit of the time,    some 
of the time,  a little bit of the time,  none of the time 
 
During the past 4 week,s how much of the time has your physical health or emotional problems 
interfered with your social activities (like visiting friends relatives etc) 
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All of the time,  most of the time,  some of the time,  a little bit of the time, none of 
the time 
 
Symptomatic hormonal changes: 
 
For Women: 
 
Do you have regular periods: Y/N 
If the answer is no, have you had a period in the past year:  Y/N 
 
Have you noticed any of the following: 
Weight gain : Y/N 
Hot flashes: Y/N 
Night sweats: Y/N 
Vaginal drynesss: Y/N 
Joint pain: Y/N 
Fatigue: Y/N 
Memory problems: Y/N 
Mood swings: Y/N 
Urinary tract infections: Y/N 
Decreased libido (sex drive) : Y/N 
Score : /10 
 
For Men: 
Have you notice any of the following: 
Weight gain: Y/N 
Difficulty building muscle mass: Y/N 
Erectile dysfunction: Y/N 
Joint pain: Y/N 
Fatigue: Y/N 
Memory problems: Y/N 
Mood swings: Y/N 
Decreased libido (sex drive) : Y/N 
Score: /9 
 
Weight history: 
What is your current weight? 
What was your weight one year ago? 
What was your weight at age 25? 
What is the most that you have weighed? 
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Appendix B: STOP-BANG Questionnaire (49) 
 
1. Snoring: Do you snore loudly (loud enough to be heard through closed doors)? 
Yes No 
2. Tired: Do you often feel tired, fatigued, or sleepy during daytime? 
Yes No 
3. Observed: Has anyone observed you stop breathing during your sleep? 
Yes No 
4. Blood pressure: Do you have or are you being treated for high blood pressure? 
Yes No 
5. BMI: BMI more than 35 kg m−2? 
Yes No 
6. Age: Age over 50 yr old? 
Yes No 
7. Neck circumference: Neck circumference >40 cm? 
Yes No 
8. Gender: Male? 
Yes No 
 
